Pacira BioSciences Inc (PCRX)
16.57
-0.03
(-0.18%)
USD |
NASDAQ |
Nov 01, 16:00
16.55
-0.02
(-0.12%)
After-Hours: 20:00
Pacira BioSciences Enterprise Value: 949.40M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 949.40M |
| October 31, 2024 | 950.78M |
| October 30, 2024 | 963.23M |
| October 29, 2024 | 977.53M |
| October 28, 2024 | 975.23M |
| October 25, 2024 | 961.39M |
| October 24, 2024 | 970.15M |
| October 23, 2024 | 986.76M |
| October 22, 2024 | 998.29M |
| October 21, 2024 | 984.45M |
| October 18, 2024 | 991.83M |
| October 17, 2024 | 966.92M |
| October 16, 2024 | 952.16M |
| October 15, 2024 | 954.93M |
| October 14, 2024 | 937.86M |
| October 11, 2024 | 933.25M |
| October 10, 2024 | 900.50M |
| October 09, 2024 | 903.73M |
| October 08, 2024 | 907.42M |
| October 07, 2024 | 922.64M |
| October 04, 2024 | 946.86M |
| October 03, 2024 | 918.03M |
| October 02, 2024 | 901.42M |
| October 01, 2024 | 890.82M |
| September 30, 2024 | 879.28M |
| Date | Value |
|---|---|
| September 27, 2024 | 855.76M |
| September 26, 2024 | 846.07M |
| September 25, 2024 | 826.70M |
| September 24, 2024 | 842.84M |
| September 23, 2024 | 843.77M |
| September 20, 2024 | 855.30M |
| September 19, 2024 | 862.68M |
| September 18, 2024 | 860.83M |
| September 17, 2024 | 846.76M |
| September 16, 2024 | 807.33M |
| September 13, 2024 | 789.80M |
| September 12, 2024 | 772.27M |
| September 11, 2024 | 784.72M |
| September 10, 2024 | 796.26M |
| September 09, 2024 | 795.33M |
| September 06, 2024 | 823.93M |
| September 05, 2024 | 862.22M |
| September 04, 2024 | 883.44M |
| September 03, 2024 | 885.28M |
| August 30, 2024 | 902.81M |
| August 29, 2024 | 893.58M |
| August 28, 2024 | 872.36M |
| August 27, 2024 | 852.99M |
| August 26, 2024 | 852.99M |
| August 23, 2024 | 839.61M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
724.76M
Minimum
Aug 09 2024
4.150B
Maximum
Apr 08 2022
2.253B
Average
2.258B
Median
Sep 14 2021
Enterprise Value Benchmarks
| Cyclo Therapeutics Inc | 22.30M |
| Revance Therapeutics Inc | 802.59M |
| NovaBay Pharmaceuticals Inc | 3.615M |
| Palatin Technologies Inc | 13.93M |
| iBio Inc | 9.837M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 18.89M |
| Revenue (Quarterly) | 178.02M |
| Total Expenses (Quarterly) | 147.05M |
| EPS Diluted (Quarterly) | 0.39 |
| Gross Profit Margin (Quarterly) | 75.14% |
| Profit Margin (Quarterly) | 10.61% |
| Earnings Yield | 8.03% |
| Operating Earnings Yield | 10.91% |
| Normalized Earnings Yield | 8.025 |